Welcome to our dedicated page for Cyclerion Therapeutics SEC filings (Ticker: CYCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding a lab notebook. Cyclerion Therapeutics packs pages of sGC pharmacology data, trial protocols, and milestone royalty terms into every document, making it hard to spot cash-runway risks or FDA-related 8-K updates.
Stock Titan removes that barrier. Our AI engine parses each Cyclerion filing the moment it hits EDGAR, then delivers plain-English highlights—whether you’re skimming the Cyclerion Therapeutics quarterly earnings report 10-Q filing for R&D spend, or need Cyclerion insider trading Form 4 transactions in real time. Investors can instantly compare segments, track Cyclerion executive stock transactions Form 4, or dive into a Cyclerion annual report 10-K simplified summary without wading through clinical jargon.
Every document type is covered: 8-K material events explained when trial data drop, proxy statement executive compensation details for governance checks, and Form S-3 shelves that fund future studies. Use cases include:
- Flagging Cyclerion Form 4 insider transactions real-time before catalysts
- Monitoring trial-cost trends via our Cyclerion earnings report filing analysis
- Understanding Cyclerion SEC documents with AI to gauge licensing revenue potential
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) filed a Current Report on Form 8-K disclosing the formal voting results from its 16 June 2025 Annual Meeting of Shareholders.
- Election of directors: All six nominees—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins and Dina Katabi—were re-elected, each receiving roughly 1.32–1.34 million votes FOR versus 63–73 thousand AGAINST; 743,285 broker non-votes were recorded.
- Auditor ratification: Ernst & Young LLP was confirmed for fiscal 2025 with 2,072,684 FOR, 57,547 AGAINST and 147 ABSTAIN.
- Say-on-pay (advisory): Executive compensation passed (1,312,697 FOR; 78,221 AGAINST; 6,203 ABSTAIN).
- Say-on-pay frequency: Shareholders favored an annual vote (827,809 one-year vs. 562,965 three-year).
- Adjournment authority: The option to adjourn, if necessary, also passed (2,036,703 FOR; 84,719 AGAINST; 18,984 ABSTAIN).
The filing is procedural, reinforces existing governance structures and contains no new financial, operational or strategic disclosures likely to affect the company’s near-term outlook.